The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
References (125)
- et al.
High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation
Lancet
(1982) - et al.
Nortriptyline and antipyrine clearance in relation to debrisosquine hydroxylation in man
Life Sci.
(1980) - et al.
Slow hydroxylation of nortripyline and concomitant poor debrisoquine hydroxylation: clinical implications
Lancet
(1981) - et al.
Polymorphic O-demethylation of codeine
Lancet
(1988) - et al.
Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4. hydroxylation (cytochrome P-450dbl/bufl)
Biochem. biophys. Res. Commun.
(1988) - et al.
Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism
Biochem. Pharmac.
(1988) - et al.
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine like compounds
Life Sci.
(1967) - et al.
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism
Lancet
(1984) The polymorphic oxidation of beta-adrenoceptor antagonists
Pharmac. Ther.
(1989)- et al.
Polymorphic hydroxylation of debrisoquine in man
Lancet
(1977)
The genetic polymorphism of debrisoquine/sparteine metabolism—Metabolism mechanisms
Pharmac. Ther.
(1990)
Sparteine sulphate: A potent capricious oxytoxic
Am. J. Obstet. Gynec.
(1966)
Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
Life Sci.
(1984)
Interindividual variation in the metabolism of dextromethorphan
Int. J. Pharmaceut.
(1983)
Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation
Am. Heart. J.
(1983)
Relationship of N-demethylation of amiflamine and its metabolite to debrosoquine hydroxylation polymorphism
Clin. Pharmac. Ther.
(1984)
Editorial: Polymorphic drug oxidation—Much ado about nothing?
Lancet
(1984)
A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phyogenetic time frame for the pathway
Clin. Pharmac. Ther.
(1988)
The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metabolizers
Clin. Pharmac. Ther.
(1988)
Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers
Br. J. clin. Pharmac.
(1989)
Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites
Eur. J. clin. Pharmac.
(1986)
Is there a genetic factor in flecainide toxicity?
Br. med. J.
(1988)
Debrisoquin oxidation polymorphism in a Spanish population
Clin. Pharmac. Ther.
(1988)
Guide to drug dosage in renal failure
Extremely rapid hydroxylation of debrisoquine. A case report with implication for treatment with nortriptyline and other tricyclic antidepressants
Ther. Drug Monit.
(1985)
Rapid conjugation in an extremely rapid hydroxylator of debrisoquine: A case report supporting a corregulation of certain phase I and II metabolic reactions
Ther. Drug Monit
(1988)
Sparteine oxidation polymorphism in Greenlanders living in Denmark
Br. J. clin. Pharmac.
(1986)
First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype
Clin. Pharmac. Ther.
(1988)
Sparteine oxidation polymorphism in Denmark
Acta pharmac. Toxic.
(1985)
Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics
Eur. J. clin. Pharmac.
(1986)
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphisms
Eur. J. clin. Pharmac.
(1986)
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment
Pharmac. Toxic.
(1987)
Adverse effects from metoprotol are not generally associated with oxidation status
Br. J. clin. Pharmac.
(1984)
Polymorphic hydroxylation of perhexiline maleate in man
J. med. Genet.
(1984)
Disposition of perphenazine is related to the polymorphic debrisoquin hydroxylation in man
Clin. Pharmac. Ther.
(1989)
Stereo- and regioselective of hepatic oxidation in man—effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation
Eur. J. clin. Pharmac.
(1986)
Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450dbl activity
Clin. Pharmac. Ther.
(1989)
Impact of genetic and environmental factors on codeine analgesia
Clin. Pharmac. Ther.
(1989)
Drug hydroxylation disorders (debrisoquine type) in a random sample of the Swiss population
Schweiz. Med. Wochenschr.
(1982)
Ein neuentdeckter Defekt im Arzneimittel-stoffwechsel des Menschen: Die fehlende N-Oxidation des Spartein
(1975)
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans
Eur. J. clin. Pharmac.
(1985)
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect
Eur. J. clin. Pharmac.
(1979)
The influence of enzyme induction on polymorphism sparteine oxidation
Br. J. clin. Pharmac.
(1986)
The genetic polymorphism of sparteine metabolism
Xenobiotica
(1986)
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
J. met. Genet.
(1980)
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions
J. med. Genet.
(1983)
Single dose pharmacokinetics of tomoxetibe in poor and extensive metabolisers of debrisoquine
Br. J. clin. Pharmac.
(1988)
Debrisoquine hydroxylation polymorphism in Hungary
Orv. Hetil.
(1986)
Frequencies of the different mutant alleles of the sparteine/debrisoquine polymorphism
Naunyn-Schmiedebergs Arch. Pharmac.
(1989)
Discovery of altered pharmacokinetics of CGP 15210G in poor hydroxylators of debrisoquine during early drug development
Br. J. clin. Pharmac.
(1985)
Cited by (379)
Pathways of drug metabolism
2021, Atkinson's Principles of Clinical Pharmacology7.13 Oxidation: Stereoselective Oxidations with Cytochrome P450 Monooxygenases
2012, Comprehensive ChiralityRat CYP2D2, not 2D1, is functionally conserved with human CYP2D6 in endogenous morphine formation
2012, FEBS LettersCitation Excerpt :Human CYP2D6 is involved in the oxidation of about 30% of clinically relevant drugs including the morphine precursor codeine [1,2]. The enzyme has been connected to a phenomenon known as the debrisoquine/sparteine metabolism of drug oxidation which is caused by aberrant metabolism patterns due to the absence or deficiency of functional allelic variants of CYP2D6 [3]. At least 112 allelic variants of CYP2D6 have been described since the discovery of the genetic polymorphism resulting in a total of four individual phenotypes: poor, intermediate, extensive and ultrarapid metabolizers [4].
Pharmacogenetics-in veterinary-anesthesia-and analgesia
2024, Pharmacology in Veterinary Anesthesia and AnalgesiaDevelopment of a Sensitive and Rapid HPLC–MS Method for Dihydrocodeine and Dihydromorphine: Application to Bioequivalence Studies
2022, Journal of Chromatographic Science
Copyright © 1990 Published by Elsevier Inc.